Skip to main content

Table 1 Statistical power with 75 patients

From: ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer

Randomisation

Surv1

Surv2

HR

1:1

0.05

0.208

0.52

2:3

0.05

0.198

0.54

1:2

0.05

0.198

0.54

  1. Surv1 is the survival probability in the control group at the end of the study. Surv2 is the survival probability in the experimental group. HR, hazard ratio, effect size of the experimental to the control group
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us